Disc Medicine Stock Performance
| IRON Stock | 64.57 1.00 1.53% |
The firm shows a Beta (market volatility) of 0.11, which means not very significant fluctuations relative to the market. As returns on the market increase, Disc Medicine's returns are expected to increase less than the market. However, during the bear market, the loss of holding Disc Medicine is expected to be smaller as well. At this point, Disc Medicine has a negative expected return of -0.44%. Please make sure to confirm Disc Medicine's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Disc Medicine performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Disc Medicine has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 17.19 | Five Day Return (9.46) | Year To Date Return (17.09) | Ten Year Return (36.34) | All Time Return (36.34) |
Last Split Factor 1:30 | Last Split Date 2022-12-30 |
1 | Disc Medicine Builds Momentum In Clinical Science | 12/08/2025 |
2 | Disposition of 1371 shares by Bitterman Kevin of Disc Medicine at 93.8 subject to Rule 16b-3 | 12/12/2025 |
3 | Disposition of 300 shares by Savage William Jacob of Disc Medicine at 92.23 subject to Rule 16b-3 | 12/15/2025 |
4 | Disc Medicine Is Down 13.5 percent After FDA Scrutiny Clouds Bitopertin Pathway And Insider Sales - Whats Changed | 12/23/2025 |
5 | Disposition of 6500 shares by Khara Rahul of Disc Medicine at 13.5 subject to Rule 16b-3 | 01/02/2026 |
6 | How Disc Medicines New HR Chief and Bitopertin Review Could Shape IRONs Commercial Readiness | 01/14/2026 |
7 | Disc Medicine Valuation Check As Bitopertin Wins Priority FDA Review And Commercial Plans Advance | 01/16/2026 |
8 | Disposition of 1000 shares by Khara Rahul of Disc Medicine at 13.5 subject to Rule 16b-3 | 01/20/2026 |
9 | Y Intercept Hong Kong Ltd Purchases 33,905 Shares of Disc Medicine, Inc. IRON | 01/28/2026 |
10 | Acquisition by Quisel John D of 82800 shares of Disc Medicine at 74.75 subject to Rule 16b-3 | 02/10/2026 |
11 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON | 02/12/2026 |
12 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of InvestorsofDisc Medicine, Inc.- IRON | 02/17/2026 |
| Begin Period Cash Flow | 360.6 M | |
| Total Cashflows From Investing Activities | -292.3 M |
Disc Medicine Relative Risk vs. Return Landscape
If you would invest 9,035 in Disc Medicine on November 20, 2025 and sell it today you would lose (2,578) from holding Disc Medicine or give up 28.53% of portfolio value over 90 days. Disc Medicine is currently does not generate positive expected returns and assumes 4.7431% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Disc, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Disc Medicine Target Price Odds to finish over Current Price
The tendency of Disc Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 64.57 | 90 days | 64.57 | about 99.0 |
Based on a normal probability distribution, the odds of Disc Medicine to move above the current price in 90 days from now is about 99.0 (This Disc Medicine probability density function shows the probability of Disc Stock to fall within a particular range of prices over 90 days) .
Disc Medicine Price Density |
| Price |
Predictive Modules for Disc Medicine
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Disc Medicine. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Disc Medicine Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Disc Medicine is not an exception. The market had few large corrections towards the Disc Medicine's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Disc Medicine, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Disc Medicine within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.32 | |
β | Beta against Dow Jones | 0.11 | |
σ | Overall volatility | 8.17 | |
Ir | Information ratio | -0.08 |
Disc Medicine Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Disc Medicine for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Disc Medicine can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Disc Medicine generated a negative expected return over the last 90 days | |
| Disc Medicine has high historical volatility and very poor performance | |
| Net Loss for the year was (109.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Disc Medicine generates negative cash flow from operations | |
| Disc Medicine has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of InvestorsofDisc Medicine, Inc.- IRON |
Disc Medicine Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Disc Stock often depends not only on the future outlook of the current and potential Disc Medicine's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Disc Medicine's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27.6 M | |
| Cash And Short Term Investments | 489.9 M |
Disc Medicine Fundamentals Growth
Disc Stock prices reflect investors' perceptions of the future prospects and financial health of Disc Medicine, and Disc Medicine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Disc Stock performance.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 1.52 B | ||||
| Shares Outstanding | 37.75 M | ||||
| Price To Book | 3.68 X | ||||
| EBITDA | (108.27 M) | ||||
| Net Income | (109.36 M) | ||||
| Total Debt | 30 M | ||||
| Book Value Per Share | 16.38 X | ||||
| Cash Flow From Operations | (93.93 M) | ||||
| Earnings Per Share | (5.38) X | ||||
| Market Capitalization | 2.11 B | ||||
| Total Asset | 496.77 M | ||||
| Retained Earnings | (298 M) | ||||
| Working Capital | 470.3 M | ||||
About Disc Medicine Performance
By examining Disc Medicine's fundamental ratios, stakeholders can obtain critical insights into Disc Medicine's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Disc Medicine is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.32) | (0.30) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.28) | (0.27) |
Things to note about Disc Medicine performance evaluation
Checking the ongoing alerts about Disc Medicine for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Disc Medicine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Disc Medicine generated a negative expected return over the last 90 days | |
| Disc Medicine has high historical volatility and very poor performance | |
| Net Loss for the year was (109.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Disc Medicine generates negative cash flow from operations | |
| Disc Medicine has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of InvestorsofDisc Medicine, Inc.- IRON |
- Analyzing Disc Medicine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Disc Medicine's stock is overvalued or undervalued compared to its peers.
- Examining Disc Medicine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Disc Medicine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Disc Medicine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Disc Medicine's stock. These opinions can provide insight into Disc Medicine's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Disc Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Will Biotechnology sector continue expanding? Could Disc diversify its offerings? Factors like these will boost the valuation of Disc Medicine. Market participants price Disc higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Disc Medicine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Disc Medicine using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Disc Medicine's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Disc Medicine's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Disc Medicine's market price signifies the transaction level at which participants voluntarily complete trades.